Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as telithromycin (HMR3647)
telithromycin · 5 trials · 6 indications
| Name | Type | Description |
|---|---|---|
| telithromycin (HMR3647) | DRUG | - |
| Telithromycin | DRUG | - |
Inclusion Criteria: * Outpatients of weight from 7.0 kg. * For respiratory tract infections:subjects diagnosed with mild or moderate respiratory tract infection (excluding pneumonia) based on a fever (≥ 38°C) or C-Reactive Protein positive, clinical symptoms/signs, and laboratory findings. * For de...
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 28 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | Tilrekimig, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
Telithromycin is a small molecule antibacterial studied for respiratory and related infections, including community-acquired pneumonia, acute otitis media, maxillary sinusitis, and other infections in children and adults. It has also been studied in asthma. Development has focused on these infectious and respiratory indications.
Telithromycin is developed by Sanofi, which trades under the ticker SNY. The company has sponsored Phase 3 clinical studies of the drug in Japan and the United States across pneumonia, otitis media, maxillary sinusitis, and pediatric infections.
Telithromycin is in Phase 3 clinical development. It is investigational and is not described as approved. The Phase 3 program includes completed trials in community-acquired pneumonia, acute otitis media, maxillary sinusitis, and infections in children.
Completed Phase 3 trials include NCT00638859 in children with community-acquired pneumonia, NCT00638534 in children with acute otitis media, NCT00537563 comparing telithromycin with moxifloxacin in maxillary sinusitis, and NCT00408135 evaluating safety, efficacy, and acceptability in children with infections.
Yes. Telithromycin is also known as HMR3647, so the two names refer to the same compound. Searches for either name lead to the same Sanofi Phase 3 small molecule program in respiratory and infectious disease indications.
In children, telithromycin has been studied in Phase 3 trials for community-acquired pneumonia, acute otitis media, and other infections. These Japanese studies enrolled children from 6 months of age, and all of them have been completed.